

Remarks

Claims 1 – 51 are pending in the application. Claims 24-25, 31, 32, 33, 34, 36-43 are as originally presented. Claims 6, 13, 16-18, 21, 26, 35, are cancelled. Claims 1-4, 5, 7, 8, 9, 10, 11, 12, 19, 20, 22-23, 27-30 are currently amended. Claims 44-51 are newly added. Claim 44 – 47 are comparable to claim 1 – 4 and claim 48 – 51 are comparable to claims 9-12 with the addition of the phrase “unfractionated cells of a lysed blood sample”. Support for this phrase is found in Example 5 of the specification. No new matter has been added.

In response to the Restriction Requirement dated October 2, 2006, Applicant elects **Group I** and claims drawn to a method of identifying biomarkers of Alzheimer’s Disease and a Method of detecting a statistically significant difference in expression indicative of Alzheimer’s Disease.

Support for the amended claims is found through the specification and in the originally filed claims. In particular, support for methods of identifying biomarkers of and diagnosing Alzheimer’s Disease using the methods as defined in the claims is found throughout the specification, including Example 44. No new matter has been added.

A petition for extension of time is attached. However, should any fees be required to ensure consideration of this response, the Commissioner is authorized to charge Deposit Account 04-1105, Reference No. 2055R(204231).

Respectfully submitted,

Date: April 2, 2007

57849
Kathleen M. Williams
Name: Kathleen M. Williams
Registration No.: 34,380
Customer No.: 29933
Edwards Angell Palmer & Dodge LLP
P.O. Box 55874
Boston, MA 02205
Tel: 617-239-0100